TechNavio's analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market.
TechNavio's report, the Global RNAi Drug Delivery Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global RNAi Drug Delivery market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp..
Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc.
Key questions answered in this report:
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Technology Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Prominent Vendors
17. Key Vendor Analysis
17.1 Alnylam Pharmaceuticals Inc.
17.1.1 Business Overview
17.1.2 Key Information
17.1.3 SWOT Analysis
17.2 Isis Pharmaceuticals Inc.
17.2.1 Business Overview
17.2.2 Key Information
17.2.3 SWOT Analysis
17.3 Merck & Co. Inc.
17.3.1 Business Overview
17.3.2 Business Segmentation
17.3.3 Key Information
17.3.4 SWOT Analysis
17.4 Tekimira Pharmaceuticals Corp.
17.4.1 Business Overview
17.4.2 Key Information
17.4.3 SWOT Analysis
18. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global RNAi Drug Delivery Market 2013-2018 (US$ billion)
Exhibit 3: Global RNAi Drug delivery market-Segmentation by Types
Exhibit 4: Global RNAi drug delivery Market By Types 2013
Exhibit 5: Global RNAi Drug Delivery Market By Geography 2013
Exhibit 6: Business Segmentation of Merck& Co. Inc.